Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
13:24:00 EDT Thu 16 May 2024
Enter Symbol
or Name
USA
CA



News for U:JAGX from 2023-05-17 to 2024-05-16 - 85 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-14 08:11U:JAGXNews ReleaseJaguar Health Reports First Quarter 2024 Financial Results
2024-05-13 12:39U:JAGXNews ReleaseREMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
2024-05-09 10:36U:JAGXNews ReleaseJaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe
2024-05-08 09:01U:JAGXNews ReleaseJaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates
2024-05-06 08:32U:JAGXNews ReleaseCrofelemer, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company's Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs
2024-04-29 08:32U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)
2024-04-22 10:01U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care
2024-04-22 08:46U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Care
2024-04-18 08:42U:JAGXNews ReleaseJaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
2024-04-16 08:33U:JAGXNews ReleaseJaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
2024-04-09 16:17U:JAGXNews ReleaseJaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
2024-04-08 08:32U:JAGXNews ReleaseJaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
2024-04-02 08:55U:JAGXNews ReleaseJaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar International
2024-04-01 08:03U:JAGXNews ReleaseJaguar Health Reports 2023 Financial Results
2024-03-27 08:32U:JAGXNews ReleaseJaguar Health to Hold Investor Webcast Monday, April 1st at 8:30 AM Eastern Regarding Q4 2023 Financials & Corporate Updates
2024-03-20 08:32U:JAGXNews ReleaseGEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market
2024-02-23 08:33U:JAGXNews ReleaseJaguar Health Requests and Receives Hearing on Nasdaq Listing Compliance
2024-02-15 08:33U:JAGXNews ReleaseJaguar Health Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
2024-02-14 08:32U:JAGXNews ReleaseJaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
2024-02-12 08:33U:JAGXNews ReleaseJaguar Health Announces Submission of Orphan Drug Designation Application to the FDA for Crofelemer for Cholera-Related Diarrhea
2024-01-30 08:48U:JAGXNews ReleaseMagdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Study Indicates Psychoactive Activity of Medicinal Plant Utilized for Centuries by Indigenous Peoples in Tropical Regions
2024-01-29 08:32U:JAGXNews ReleaseJaguar Health to Present January 31 at The Microcap Conference and Participate in a Fireside Chat February 1 at the Lytham Partners Investor Select Conference
2024-01-25 08:34U:JAGXNews ReleaseDog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health ¢ € ™s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)
2024-01-05 16:16U:JAGXNews ReleaseJaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2024-01-04 08:31U:JAGXNews ReleaseIssuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)
2023-12-11 08:31U:JAGXNews ReleaseA Majority of Subjects in Jaguar Health's Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Stage II
2023-12-07 08:33U:JAGXNews ReleaseMASCC (Multinational Association of Supportive Care in Cancer) Webinar on GI Toxicities from Cancer Therapies Made Possible by Grant From Napo Pharmaceuticals, a Jaguar Health Family Company
2023-12-06 08:33U:JAGXNews ReleaseStudy Data on Quality of Life for Breast Cancer Patients and Survivors, Supported by Napo Pharmaceuticals (a Jaguar Health Family Company), Published on San Antonio Breast Cancer Symposium (SABCS) Website
2023-12-04 08:33U:JAGXNews ReleaseFDA Approves Renewal of Canalevia-CA1, Jaguar Health ¢ € ™s Drug for Chemotherapy-Induced Diarrhea in Dogs
2023-11-30 08:33U:JAGXNews ReleaseJaguar Health to Present December 5 at the MedInvest Oncology Investor Conference
2023-11-21 08:32U:JAGXNews ReleaseTop Line Data for Jaguar Health ¢ € ™s Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Forthcoming
2023-11-14 21:00U:JAGXNews ReleaseFILAMENT HEALTH ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
2023-11-14 08:02U:JAGXNews ReleaseJaguar Health Reports Third Quarter 2023 Financial Results
2023-11-10 16:16U:JAGXNews ReleaseJaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2023-11-09 08:32U:JAGXNews ReleaseBreast Cancer Related Results of Groundbreaking Napo Pharmaceuticals (a Jaguar Health Family Company) Supported Study on Quality of Life for Cancer Patients and Survivors Accepted for Presentation at the December 2023 San Antonio Breast Cancer Symposium
2023-11-08 10:26U:JAGXNews ReleaseJaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
2023-11-08 08:33U:JAGXNews ReleaseJaguar Health to Hold Investor Webcast Tuesday, November 14th at 8:30 AM Eastern Regarding Q3 2023 Financials & Corporate Updates
2023-11-07 08:33U:JAGXNews ReleaseREMINDER: Jaguar Health to Host Virtual Educational Webinar on Rare Intestinal Failure Diseases with Leading Gastroenterologists and Nutrition Experts November 8th from 1:00 PM to 2:30 PM EST
2023-11-02 08:33U:JAGXNews ReleaseJaguar Health Enters Exclusive Crofelemer Revenue Sharing License and Commercialization Agreement with Quadri Pharmaceuticals Store for Rare Intestinal Failure Diseases in Middle East Markets
2023-11-01 08:32U:JAGXNews ReleaseIssuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
2023-10-30 08:32U:JAGXNews ReleaseMagdalena Biosciences, a Joint Venture between Jaguar Health and Filament Health, Receives Second Tranche of Funding from One Small Planet
2023-10-23 08:34U:JAGXNews ReleaseMagdalena Biosciences Initiates Preclinical Study to Evaluate Plant Extracts to Treat Depression, Anxiety, ADHD and Other Mental Health Indications
2023-10-19 08:32U:JAGXNews ReleaseIndependent Study Conducted at Boston Children's Hospital, Harvard Medical School, Shows Potential Utility of Jaguar Health's Crofelemer for Treatment of MVID, a Rare Childhood Disease
2023-10-18 08:33U:JAGXNews ReleaseNapo Pharmaceuticals to Exhibit at the October 25-28 Annual Association of Nurses in AIDS Care (ANAC) Conference for Mytesi, the Company ¢ € ™s FDA-Approved Prescription Drug
2023-10-12 08:32U:JAGXNews ReleaseJaguar Health to Present October 17 at the Lytham Partners Fall 2023 Investor Conference and October 18 at the BIO Investor Forum
2023-10-10 08:35U:JAGXNews ReleaseJaguar Animal Health Exhibiting at October 12-14 VCS Annual Conference for Canalevia-CA1, the Company's FDA Conditionally Approved Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
2023-09-28 08:35U:JAGXNews ReleaseJaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
2023-09-27 08:33U:JAGXNews ReleaseJaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise Diarrhea
2023-09-26 08:32U:JAGXNews ReleaseNapo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
2023-09-21 07:33U:JAGXNews ReleaseJaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
2023-09-21 07:30U:JAGXNews ReleaseFILAMENT HEALTH AND JAGUAR HEALTH JOINT VENTURE MAGDALENA BIOSCIENCES COMPLETES IMPORT OF COCA LEAF FROM PERU
2023-09-14 08:34U:JAGXNews ReleaseJaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
2023-09-13 08:31U:JAGXNews ReleasePatent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
2023-09-12 08:32U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
2023-09-11 09:07U:JAGXNews ReleaseJaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
2023-09-11 08:33U:JAGXNews ReleaseJaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
2023-09-07 08:33U:JAGXNews ReleaseJaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
2023-08-30 08:31U:JAGXNews ReleaseThe Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
2023-08-28 08:31U:JAGXNews ReleaseJaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
2023-08-24 07:02U:JAGXNews ReleaseJaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
2023-08-17 08:30U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
2023-08-16 08:31U:JAGXNews ReleaseNapo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
2023-08-14 08:00U:JAGXNews ReleaseJaguar Health Reports Second Quarter 2023 Financial Results
2023-08-10 08:31U:JAGXNews ReleaseJaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
2023-08-08 08:31U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
2023-08-07 08:31U:JAGXNews ReleaseIndependent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
2023-08-03 08:31U:JAGXNews ReleaseJaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
2023-08-02 08:31U:JAGXNews ReleaseREMINDER: Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton" August 5th
2023-08-01 08:42U:JAGXNews ReleaseJaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
2023-07-27 08:31U:JAGXNews ReleaseIn Honor of World Nature Conservation Day, Jaguar Health Announces Planting of More Than 1.1 Million Trees in Peruvian Amazon
2023-07-26 08:31U:JAGXNews ReleaseJaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
2023-07-25 08:34U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton"
2023-07-07 16:16U:JAGXNews ReleaseJaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
2023-06-28 08:31U:JAGXNews ReleaseNapo Pharmaceuticals, a Jaguar Health Company, Submits Investigational New Drug (IND) Application to FDA for Microvillus Inclusion Disease
2023-06-26 08:31U:JAGXNews ReleaseFirst U.S.-Based Canine Cancer Registry, Founded by Jaguar Health, Joins International Network to Help Advance Canine and Human Cancer Research
2023-06-22 08:31U:JAGXNews ReleaseJaguar Health Launching AI-Driven Social Media Disease Awareness Education Series Regarding Cancer Therapy-Related Diarrhea in Dogs and People
2023-06-20 08:31U:JAGXNews ReleaseJaguar Health Subsidiary Becomes Corporate Partner of Multinational Association of Supportive Care in Cancer (MASCC)
2023-06-15 08:31U:JAGXNews ReleaseJaguar Health to Present June 21st at MedInvest Oncology Investor Conference
2023-06-14 08:31U:JAGXNews ReleaseLadenburg Thalmann to Host Virtual Discussion June 22nd with Jaguar Health CEO and Leading Patient Advocates on Impact of Cancer Therapy-related Diarrhea on Patients & Importance of the Patient Voice in Supportive Care
2023-06-08 15:01U:JAGXNews ReleaseCanine and Child Cancer Research Advocates Call for Support as Capitol Hill "Goes to the Dogs"
2023-06-07 08:31U:JAGXNews ReleaseEuropean Pharmaceutical Industry Leader and Entrepreneur Massimo Radaelli, PhD Named Commander of the Italian Republic for Special Merits
2023-05-25 08:31U:JAGXNews ReleaseJaguar Announces Over-Enrollment in its Pivotal Phase 3 OnTarget Trial of Crofelemer for Prophylaxis of Cancer Therapy-Related Diarrhea
2023-05-24 08:31U:JAGXNews ReleaseBoard Certified Patient Advocate Stacey Tinianov, MPH, Joins Jaguar Health's Scientific Advisory Board
2023-05-23 08:32U:JAGXNews ReleaseTake C.H.A.R.G.E. Registry Marks One-Year Anniversary on National Canine Cancer Awareness Day, With Database Grown 40%
2023-05-19 16:15U:JAGXNews ReleaseJaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)